白蛋白结合型紫杉醇联合环磷酰胺在早期乳腺癌辅助化疗中的安全性

The safety of albumin-bound paclitaxel combined with cyclophosphamide in adjuvant chemotherapy for early breast cancer

目的探讨白蛋白结合型紫杉醇联合环磷酰胺在早期乳腺癌辅助化疗中的安全性。方法选取2018年10月至2019年12月济宁医学院附属医院乳腺外科收治的83例早期乳腺癌术后患者作为研究对象,根据化疗方案不同分为白蛋白结合型紫杉醇组(n=37)与多西他赛组(n=46)。白蛋白结合型紫杉醇组采用白蛋白结合型紫杉醇联合环磷酰胺方案化疗,多西他赛组采用多西他赛联合环磷酰胺方案化疗,比较两组化疗不良反应发生情况。结果两组胃肠道反应、骨髓功能抑制、口腔溃疡、脱发、心脏功能损害不良反应发生率比较差异无统计学意义;两组肝功能损伤、过敏反应、周围神经炎不良反应发生率比较差异有统计学意义(P<0.05)。结论白蛋白结合型紫杉醇联合环磷酰胺在早期乳腺癌辅助化疗中安全性较高,肝功损伤、过敏反应及周围神经炎不良反应较轻,值得临床推广应用。

Objective To investigate the safety of albumin-binding paclitaxel combined with cyclophosphamide in adjuvant chemotherapy for early breast cancer.Methods 83 patients with early breast cancer who were admitted to the Department of Breast Surgery,Affiliated Hospital of Jining Medical University from October 2018 to December 2019 were selected as the research subjects,and they were divided into albumin-bound paclitaxel group(n=37)and docetaxel group(n=46)according to different chemotherapy regimens.The albumin-bound paclitaxel group was treated with albumin-bound paclitaxel combined with cyclophosphamide regimen,and the docetaxel group was treated with docetaxel combined with cyclophosphamide regimen,the incidence of adverse reactions to chemotherapy was compared between the two groups.Results There was no statistically significant difference in the incidence of gastrointestinal reactions,bone marrow function suppression,oral ulcers,hair loss,and cardiac function impairment adverse reactions between the two groups;there were statistically significant difference in the incidence of liver function impairment,allergic reactions,and peripheral neuritis adverse reactions between the two groups(P<0.05).Conclusion Albumin-bound paclitaxel combined with cyclophosphamide is safe in adjuvant chemotherapy for early-stage breast cancer,and the adverse reactions of liver function damage,allergic reaction and peripheral neuritis are mild,so it is worthy of clinical promotion and application.